EP2081574A1 - Buprenorphine-containing non-pressurised spray composition for transmucosal administration - Google Patents
Buprenorphine-containing non-pressurised spray composition for transmucosal administrationInfo
- Publication number
- EP2081574A1 EP2081574A1 EP07824851A EP07824851A EP2081574A1 EP 2081574 A1 EP2081574 A1 EP 2081574A1 EP 07824851 A EP07824851 A EP 07824851A EP 07824851 A EP07824851 A EP 07824851A EP 2081574 A1 EP2081574 A1 EP 2081574A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- composition according
- buprenorphine
- ethanol
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 189
- 229960001736 buprenorphine Drugs 0.000 title claims abstract description 72
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title claims abstract description 68
- 239000007921 spray Substances 0.000 title claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 135
- 239000002904 solvent Substances 0.000 claims abstract description 45
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 16
- 239000006193 liquid solution Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229940081974 saccharin Drugs 0.000 claims description 22
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 22
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 20
- 235000019204 saccharin Nutrition 0.000 claims description 20
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 16
- 229940041616 menthol Drugs 0.000 claims description 16
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 15
- 235000019477 peppermint oil Nutrition 0.000 claims description 15
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 10
- 229940085605 saccharin sodium Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229940127240 opiate Drugs 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 2
- 239000000243 solution Substances 0.000 description 34
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 26
- 238000003860 storage Methods 0.000 description 16
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 9
- 239000003380 propellant Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 210000004877 mucosa Anatomy 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 6
- 201000009032 substance abuse Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- -1 nonoxinols Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 229940037001 sodium edetate Drugs 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 208000026251 Opioid-Related disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000005040 opiate dependence Diseases 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000006190 sub-lingual tablet Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 244000004005 Nypa fruticans Species 0.000 description 1
- 235000005305 Nypa fruticans Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940061631 citric acid acetate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000005356 container glass Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 229940041676 mucosal spray Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940013712 pineapple extract Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- FVEFRICMTUKAML-UHFFFAOYSA-M sodium tetradecyl sulfate Chemical compound [Na+].CCCCC(CC)CCC(CC(C)C)OS([O-])(=O)=O FVEFRICMTUKAML-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940095172 subutex Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Definitions
- This invention relates to compositions of buprenorphine especially pump spray compositions suitable for transmucosal, particularly sublingual, delivery.
- Buprenorphine is a partial agonist of opiate receptors which is widely used for the treatment of moderate to severe pain or in the treatment of opiate dependence.
- Buprenorphine is often described as a partial agonist (receptor stimulator)/antagonist (prevents receptor stimulation). It has important actions on two types of opiate receptors in the brain. Many of the most common opioid effects, such as euphoria, respiratory effects and reduced pain sensation, are caused by stimulation of the mu receptor. Buprenorphine stimulates this receptor, albeit at lower intensity than other opiates such as heroin or methadone. This lower level of stimulation is of benefit clinically in people with respiratory compromise but require opioid medication, such as the elderly.
- Buprenorphine is also an antagonist of the kappa opioid receptor, which is associated with some of the negative effects experienced in withdrawal, particularly depression. As buprenorphine inhibits stimulation of this receptor it may produce feelings of well-being. Finally, its disassociation from these receptors is slow, leading to a long duration of action, allowing once daily dosing and sometimes dosing every two days, making buprenorphine a versatile treatment option in treatment of drug addiction.
- buprenorphine hydrochloride A number of presentations of buprenorphine are currently available. Low-dose sub-lingual tablets, containing 0.2-0.4 mg of the drug as hydrochloride, are sold under the brand name Temgesic and are normally used for analgesic purposes. Temgesic brand of buprenorphine hydrochloride is also available as ampoules for intramuscular or slow intravenous injection. The most common formulation of buprenorphine used for the treatment of opiate dependence is sublingual tablets containing 0.4, 2 and 8 mg buprenorphine hydrochloride and available under the brand name Subutex. Using a combination of tablets, doses of up to 32 mg may be administered.
- These tablets are specifically intended for the treatment of problem drug use in patients who are being maintained in medically assisted treatment; in the case of patients undergoing withdrawal treatment, they are administered in a gradually reducing dose.
- Low-dose sublingual tablets are sometimes used for the treatment of opiate dependence, in which case multiple tablets are prescribed in order to achieve the desired dose.
- a liquid formulation for sub-lingual administration is described in GB2100985 (Todd). Specifically, this document describes formulations containing buprenorphine or a non-toxic salt thereof, but especially buprenorphine hydrochloride, dissolved in 20-30% v/v ethanol in water buffered to a pH of between 4.5-5.5 with 0.05-0.2 molar concentration of a buffering agent selected from citric acid/disodium hydrogen phosphate, sodium citrate/hydrochloric acid, lactic acid/disodium hydrogen phosphate, lactic acid/sodium lactate, sodium citrate/citric acid and sodium acetate/acetic acid, the concentration of buprenorphine being between 0.8 and 10 mg/ml (i.e.
- compositions do not appear to be sprays as the document refers to the volume of liquid that a patient can hold sublingually for a reasonable amount of time.
- mucosa for example the sublingual mucosa
- mucosa for example the sublingual mucosa
- Other mucosa to which medicaments may be administered include the nasal mucosa and buccal mucosa.
- a number of ways of administering compositions sublingually are known. For example, tablets or liquids may be held under the tongue prior to swallowing. Another method is spray delivery.
- spray delivery is preferred as it does not involve holding the composition under the tongue for an extended period of time as, for example, with a lozenge and it reduces the amount of material which is swallowed (and may enter the blood stream in a delayed manner via the gastrointestinal tract).
- spray large volumes of liquid eg greater than around 500 uL
- WO01/97780 describes a pharmaceutical composition comprising a solution of an opioid analgesic (especially fentanyl, although buprenorphine is referred to) and a propellant, for sublingual aerosol administration.
- an opioid analgesic especially fentanyl, although buprenorphine is referred to
- a propellant for sublingual aerosol administration.
- the example formulations are pressurized and therefore require complex packaging and actuation technology. Also they employ halogenated propellants which may not be environmentally friendly.
- WO01/89476 Patent et al discloses buffered compositons for transmucosal delivery. Buprenorphine is mentioned in a very long list of possible active agents and is not exemplified.
- an object of the present invention is to provide a spray composition containing buprenorphine for transmucosal, particularly sublingual, administration. Further objects of the invention are to provide a spray composition containing buprenorphine for transmucosal (eg sublingual) administration with good physical properties, especially good stability and low environmental impact, and good biological properties, especially rapid onset of activity and efficacy at relatively low doses. Such a composition would mitigate many of the disadvantages of prior art compositions containing buprenorphine.
- a non-pressurised pharmaceutical liquid solution spray composition comprising:
- the composition is non-pressurised i.e. is substantially free of any propellant.
- propellants to be substantially avoided include volatile substances which develop significant vapour pressure at ambient temperature and pressure such as lower alkanes (eg propane, butane and the like) and halogenated hydrocarbons such as CFCs (P12 etc) and hydrofluorocarbons (P134a, P227 etc) as well as other propellants commonly used in aerosol presentations.
- Use of P1 1 is also preferably substantially avoided.
- substantially free or “substantially avoided” is meant that an amount of less than 5% w/w based on weight of composition is employed, suitably less than 2% eg less than 0.1 % w/w.
- propellants are avoided altogether.
- the concentration of the buprenorphine in the composition may typically vary between 0.05 and 12% w/v, more suitably 0.1-10% w/v, eg 0.1-4% w/v or especially 2-8% w/v, for example 4-8% w/v eg 4% or 8% w/v (all figures being based on weight of buprenorphine base relative to total weight of composition).
- substantially free of chloride is meant that the formulation has a substantial absence of chloride in ionised (i.e. such that Cl " is formed in solution) or unionised form.
- the reason for the substantial absence of chloride is to avoid the precipitation of buprenorphine hydrochloride which is not highly soluble in aqueous or ethanolic solvents.
- the amount of chloride in the composition is suitably less than 3% w/w based on weight of buprenorphine eg less than 1 % w/w, eg less than 0.5% w/w for example less than 0.1 % w/w, especially when the pH of the composition is less than 7.
- the buprenorphine is employed as base or as citrate, particularly as base.
- An advantage of the invention, and in particular of use of buprenorphine in a formulation which is substantially free of chloride, is that relatively concentrated compositions can be prepared which allows for administration of high doses of buprenorphine without using excessively large metering volumes.
- concentration 4 and 8% w/v we have successfully prepared solutions of concentration 4 and 8% w/v, whereas buprenorphine hydrochloride has not proved soluble in water or ethanol at these concentrations.
- These higher concentrations of buprenorphine are achieved by using a solvent containing a significant amount of ethanol and the highest concentrations are achieved by lowering the pH with citric acid.
- WO02/094234 relates to an opioid-containing aerosol formulation for administration by inhalation.
- the formulations are all aqueous solutions with no other solvent being suggested.
- WO 03/080022 relates to aqueous solutions comprising an analgesic for intranasal administration.
- the analgesic may be buprenorphine or a salt thereof but there is no teaching that the composition should not contain chloride and indeed the examples all relate to compositions comprising buprenorphine hydrochloride.
- WO 2004/071491 relates to liquid aerosol formulations in which the solvent may contain ethanol.
- WO 2004/071491 relates to liquid aerosol formulations in which the solvent may contain ethanol.
- it would be advantageous to provide a chloride-free composition and all of the examples relate to formulations containing buprenorphine hydrochloride.
- the solvent is selected from ethanol and ethanol/water mixtures.
- ethanol is substantially the only solvent.
- concentration of ethanol in the solvent is greater than 90% w/w eg greater than 95% w/w particularly greater than 98% w/w, for example around 100% w/w (i.e. the solvent is ethanol, the presence of any water as contaminant from the atmosphere being ignored).
- use of water as solvent is substantially avoided, for example the water concentration is less than 10% w/w eg less than 5% w/w particularly less than 98% w/w, for example around 0% w/w (i.e. the composition is substantially free of water).
- avoidance of water can be advantageous especially in formulations of buprenorphine containing citrate since we have observed that such formulations have a tendency to turn pink on storage.
- the solvent comprises water as well as ethanol.
- the solvent consists of a water/ethanol mixture in which the concentration of ethanol is approximately 30-90% w/w (the balance being water) for example approximately 40-70% w/w eg around 50% w/w.
- Preferably water when employed as solvent meets the USP (US Pharmacopoeia), EP (European Pharmacopoeia) "Purified Water” standards.
- the pH of the solution may typically be between around 4 and 9.5 however will preferably be between around 4.5 and 9.
- the pH is between 4 and 6 eg between around 4.5 and 6 eg around 5 or between around 4 and 5 eg around 4.5.
- the pH is greater than 7 for instance between around 8 and 9.5 eg between around 8 and 9 eg around 8.5. It is envisaged that compositions at this higher pH will be more efficacious and/or have more rapid activity.
- buprenorphine will be more rapidly or efficiently adsorbed through the mucosa, especially the sublingual mucosa, at a pH close to the pKa of buprenorphine, which is 8.5 (Pharmaceutical Codex).
- Compositions of pH above 7 have not thus far been described in concrete terms, presumably due to the predominant use of buprenorphine hydrochloride and the problems of solubility of the active at higher pH. Such problems are substantially overcome by use of compositions of the invention.
- pH is meant the pH reading that would be obtained using a conventional pH meter eg model pH 21 1 manufactured by Hanna Instruments Ltd and Orion 420A manufactured by Thermo Electron Corporation (i.e. in water free systems the word “pH” would be construed to mean “apparent pH”).
- citrate/citric acid which does have adequate solubility in ethanolic solvents.
- citrate/citric acid is itself problematic since we have found that compositions of the invention containing citrate/citric acid and water have a tendency to turn pink on storage especially at elevated temperature. Accordingly use of buffer salts and even citrate/citric acid is preferably avoided.
- phosphate containing buffers eg phosphate and protonated derivatives such as hydrogen and dihydrogen phosphate
- the amount of phosphate in the composition is suitably less than 3% w/w based on weight of buprenorphine eg less than 1 % w/w, eg less than 0.5% w/w for example less than 0.1 % w/w especially when the pH of the composition is less than 7.
- citric acid is useful to enhance the solubility of buprenorphine base in ethanolic solvents (eg to concentrations of 4% w/v or higher eg 4-8% w/w (based on total weight of composition) particularly 5-8% w/w).
- the solvent may (most suitably) be essentially ethanol (eg 100% ethanol) or may (alternatively) contain water (eg ethanol/water 1 :1 ).
- citric acid may be employed at a concentration of around 0.1-10% w/w eg 0.2-5% w/v eg 0.2-2% w/w.
- the pH of buprenorphine base in ethanol is not significantly affected by buprenorphine concentration.
- saccharin may be effectively employed to lower the pH of buprenorphine base compositions, and is particularly useful in achieving a pH in the range 4-6, particularly 4.5-6 eg around 5.
- the pH lowering effect of saccharin lessens with increased buprenorphine concentration.
- Addition of menthol (eg L-menthol) or peppermint oil has relatively little impact on pH when in conjunction with saccharin.
- saccharin sodium as well as menthol (eg L-menthol) and peppermint oil all have a modest but potentially useful effect on raising the pH of buprenorphine base compositions in ethanol, and is particularly useful in achieving a pH in the range between about 8 and 9.5 eg between around 8 and 9 eg around 8.5.
- saccharin and saccharin sodium are useful as sweeteners which improve patient acceptability.
- menthol eg L-menthol
- peppermint oil are useful as flavourings and moisturing agents which may have penetration enhancing activity.
- compositions may be further improved by including therein a number of additional formulation components.
- - sweeteners such as saccharin, saccharin sodium, sucrose, flavouring or taste-masking agents
- -moisturising agents to improve patient comfort and overcome the drying tendency of ethanol and other polar organic solvents
- peppermint oil for example peppermint oil, menthol (eg L-menthol) pineapple extract, lanolin, polypropylene glycol, polyethylene glycol.
- -mucoadherents for example carboxyvinyl polymers, chitosans, polyacrylic acid, gelatin, polyvinyl pyrrolidone.
- -preservatives for example sodium metabisulphite, benzalkonium, Nipas.
- alkyl gallates for example alkyl gallates, butylated hydroxyanisole butylated hydroxytoluene, nordihydroguaiaretic acid, tocopherols, Ascorbic acid, sodium metabisulphite
- -anionic surfactants for example magnesium stearate, sodium cetostearyl sulphate, sodium lauryl sulphate, sodium oleate, sodium stearyl fumarate, sodium tetradecyl sulphate
- -nonionic surfactants for example glyceryl monostearate, Macrogol cetostearyl ethers,
- Poloxamers polyoxyl stearates, Polysorbates, sorbitan esters, sucrose esters, Tyloxapol, propylene glycol monostearate, Quillaia, polyoxyl, caster oils, nonoxinols, lecithins and derivatives, oleic acid and derivatives, oleyl alcohol and derivatives -foaming agents for example alginic acid and salts, propylene glycol alginate, sodium lauryl sulphate, sodium cetostearyl sulphate, carbomers, hydroxyethylcellulose
- compositions according to the invention which are of higher strength (eg 4 % w/v or above), especially those containing saccharin, have a tendency to yellow on storage, especially at higher temperatures.
- a stabiliser selected from anti-oxidants (eg ascorbic acid/ascorbate) and/or a chelating agent (eg EDTA/sodium edetate) may suitably be employed.
- Suitable moisturising agents include, for example, the polar organic solvents such as glycols, especially propylene glycol, and the liquid polyethylene glycols, glycerol, methylcellulose, hypromellose, hydroxypropylcellulose, and many other substituted celluloses.
- menthol especially L-menthol.
- Menthol eg L-menthol
- flavouring the composition has moisturising effect. It may also have effect as a penetration enhancer.
- menthol eg L-menthol
- menthol is employed in a concentration range of 0.1 % to 0.75% w/w eg around 0.2% w/w.
- Peppermint oil is an alternative component which may be used in place of menthol. Peppermint is known to have incompatibilities with certain actives (eg fentanyl) however it appears to be compatible with buprenorphine. Suitably peppermint oil is employed in a concentration range of 0.1 % to 0.75% w/w eg around 0.5% w/w.
- the composition contains a sweetener.
- the sweetener is saccharin sodium.
- the concentration of saccharin sodium is around 0.1-0.9% w/w eg around 0.45% w/w.
- the composition contains saccharin.
- the concentration of saccharin is around 0.025-0.75% w/w, for example around 0.05-0.4% w/w eg around 0.05-0.1 % w/w.
- the concentration of saccharin may be varied depending on the eventual pH desired (see Figure 2).
- compositions of the invention are considered to be especially suitable.
- a suitable example composition comprises (or consists essentially of (eg consists of)):
- composition is substantially free of chloride; and wherein the pH of the composition is greater than 7.
- the pH of the composition may, for instance, be between around 8 and 9.5 eg between around
- the solvent may suitably be ethanol.
- compositions comprise saccharin sodium.
- compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
- compositions comprise a chelating agent (eg EDTA or sodium edetate).
- a chelating agent eg EDTA or sodium edetate.
- compositions comprise an anti-oxidant.
- hydroxide eg NaOH, KOH
- KOH potassium hydroxide
- the concentration of buprenorphine base is 0.1-4% w/v.
- Another suitable example composition comprises (or consist essentially of (eg consist of)):
- -a solvent selected from ethanol and ethanol/water mixtures
- composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6 eg between around 4.5 and 6 eg around 5.
- the solvent may suitably be ethanol.
- compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
- compositions comprise a chelating agent (eg EDTA or sodium edetate).
- a chelating agent eg EDTA or sodium edetate.
- compositions comprise an anti-oxidant.
- the concentration of buprenorphine base is 0.1-4% w/v.
- Another suitable example composition comprises (or consist essentially of (eg consist of)): -buprenorphine as base at a concentration of 4% w/v or more; -a solvent selected from ethanol and ethanol/water mixtures;
- composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6 eg between around 4 and 5 eg around 4.5.
- the solvent may suitably be ethanol.
- compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
- compositions comprise saccharin.
- compositions comprise a chelating agent (eg EDTA or sodium edetate).
- a chelating agent eg EDTA or sodium edetate.
- compositions comprise an anti-oxidant.
- the concentration of buprenorphine base is 4-8% w/v.
- a process for preparation of compositions of the invention comprises:
- buprenorphine as base and a solvent comprising ethanol optionally containing the other formulation ingredients (eg saccharin, saccharin sodium, menthol, peppermint oil etc) and dissolving the buprenorphine in the solvent; or
- buprenorphine as base and a solvent comprising ethanol and dissolving the buprenorphine in the solvent, then adding the other formulation ingredients (eg saccharin, saccharin sodium, menthol, peppermint oil etc); or
- compositions of the invention are homogenous and have limited or no susceptibility to dose-to-dose variation. Furthermore compositions of the present invention are characterised by good long-term physical and chemical stability.
- compositions of the invention are preferably administered transmucosally (particularly sublingually) as a spray.
- the compositions are expected to be well tolerated when administered to the sensitive sublingual mucosa and the sublingual spray administration will result in rapid onset of the therapeutic effect of the buprenorphine.
- a metered dose dispensing system comprising a sealed container containing a composition of the invention fitted with a metering pump, an actuator and a channelling device.
- the metered dose dispensing system is preferably adapted for transmucosal (particularly sublingual) administration.
- the container for the pharmaceutical liquid composition may contain a single dose of buprenorphine (which may, nevertheless be a divided dose), preferably the container will contain a plurality of doses (eg 20 to 200 doses) of buprenorphine.
- the composition could be packaged in a suitable pharmaceutical grade, plastics container, such a container would be relatively easy to open for abuse of the product. Therefore a glass container would be more suitable. Glass would shatter if attempts were made to open the pack, rendering the contents either lost or unusable due to glass fragments.
- the glass container will be coated on the exterior with a suitable moulded film of plastic to protect against shattering.
- the film may be of polypropylene.
- the material may be coloured and contain a UV absorber.
- the container glass may be colourless or more suitably may be provided with a UV protective colouring, for example amber colouring.
- the interior of the container can be coated to enhance stability of the product. Coatings include polymers and lacquers but also silicone dioxide as an unreactive coating can be used to line the inside of the container.
- the composition is non-pressurised, it is suitably administered to the patient by pump action.
- the metering dose dispensing system suitably contains a metering pump permitting a metered dose of the composition to be administered as a spray.
- Suitable metering pumps include those adapted for dispensation with the container in the upright or inverted orientation.
- the metering chamber is adapted for dispensation with the container in the upright orientation since this facilitates administration under the tongue. Accordingly the metering chamber will be in communication with the composition by means of a dip-tube.
- the metering pump is suitably a non-venting type. Suitable materials of construction include polypropylene and polyethylene.
- Example metering pumps are those manufactured by Valois (eg VP3, VP6, VP7 and VP7D) and for example those illustrated in International Patent Application No. WO01 /66089.
- Other conventional pumps include those from Rexam (eg SP270) and Calmar (eg Accupump or Mistette Mk II).
- the actuator will be designed to deliver a transmucosally (particularly a sublingually) effective dose.
- the pump may suitably be manually actuated, although assisted actuation using stored energy (eg spring or gas) may be contemplated.
- stored energy eg spring or gas
- the pump is suitably crimped onto the container neck.
- Suitable sealing materials eg thermo plastic crimp gaskets suitable for the purpose will be employed.
- a suitable aluminium ferrule purposely designed for crimping on to glass containers may suitably be employed.
- Suitable grade stainless steel springs will preferably be adopted.
- the metering pump will administer a metered volume of composition.
- Suitable metering volumes are 10-1000 uL, more suitably 50-250 uL, eg 10OuL or 200 uL, particularly 200 uL.
- a channelling device is provided to direct the liquid sprayed from the metered dose dispensing area to the appropriate part of the mouth e.g. to the sublingual cavity or if desired to the nose.
- Channelling devices are suitably fabricated from moulded plastics.
- a number of channelling devices adapted to administer sprays to the mouth or nose are known to persons skilled in the art eg
- compositions of the invention are useful in treatment or prevention of opiate dependency and abuse, particularly in the treatment or prevention of dependency on opiates such as heroin and for analgesic purposes eg for the treatment of moderate to severe pain.
- a method of treatment or prevention of opiate dependency and abuse or pain which comprises administering to a subject in need thereof an effective amount of a composition of the invention.
- a composition according to the invention in the manufacture of a medicament for the treatment or prevention of opiate dependency and abuse or pain.
- a composition of the invention for use in the treatment or prevention of opiate dependency and abuse or pain.
- the container or the dispensing system may be provided with features to prevent tampering.
- the container or the dispensing system may suitably be provided with features to prevent or discourage access to the reservoir and/or to prevent administration of more than one dose of buprenorphine at one time.
- the dispensing system in particular the actuator, may, for example, be provided with a lock-out feature to prevent administration of a second dose within a specified time interval of the first.
- Lock-out features are, for example, described in US2006191532, WO03097141 and WO0232487.
- a patient is treated by administration transmucosally (eg sublingually) of 1 to 4 actuations eg 1 or 2 actuations from the spray pump.
- transmucosal spray delivery is the ability to easily titrate patients by 1 or 2 doses as required by a single actuation. This is not the case with other forms of drug delivery (patches, lozenges, tablets, suppositories).
- compositions of the invention are useful in the treatment of animals, particularly non-human mammals (for example domestic or livestock animals) as well as humans. Accordingly pharmaceutical uses, for example uses in the treatment of pain, may be extended to veterinary uses. Dosages and methods of administration (eg the spray actuator design) will be adapted for the intended recipient as would be known to a skilled person. Examples
- compositions formed a clear colourless solution at 4, 25 and 40 0 C and remained so after 1 month storage at these temperatures.
- compositions were prepared as follows:
- compositions formed a clear colourless solution at 4, 25 and 40 0 C and remained so after 2 weeks storage (Example 8) or 1 month storage (Examples 5-7) at these temperatures.
- compositions were prepared as follows:
- compositions formed a clear colourless solution at 4, 25 and 40 0 C and remained so after 1 month storage at these temperatures.
- compositions were prepared as follows:
- Example 13 the composition formed a clear colourless solution at 4, 25 and 40 0 C. and remained so after 2 months storage at these temperatures.
- Example 14 the composition formed a clear colourless solution at 4 and 25 0 C and a clear very light yellow solution at 4O 0 C after 2 months storage at these temperatures.
- Examples 15, 16 the compositions formed a clear colourless solution at 4 and 25 0 C and a clear light yellow solution at 4O 0 C after 3.5 months storage at these temperatures.
- compositions were prepared as follows:
- Examples 17 and 18 the compositions formed a clear colourless solution at 4 and 25 0 C and a dark yellow solution at 4O 0 C after 3.5 months storage at these temperatures.
- Example 19 the composition formed a clear light yellow solution at 4 0 C, a clear yellow solution at 25 0 C and a clear dark yellow solution at 4O 0 C after 3.5 months storage at these temperatures.
- Example 20 the composition formed a clear colourless solution at 4 0 C, a clear light yellow solution at 25 0 C and a clear yellow solution at 4O 0 C after 2 months storage at these temperatures.
- compositions were prepared as follows:
- Examples 21 and 22 the compositions formed a clear colourless solution at 4, a light yellow solution at 25 0 C and a yellow solution at 4O 0 C after 3 months storage at these temperatures.
- Example 23 the composition formed a clear colourless solution at 4 0 C and 25 0 C and a clear pink solution at 4O 0 C after 3 months storage at these temperatures.
- Example 24 the composition formed a clear colourless solution at 4 0 C and 25 0 C and a clear light pink solution at 4O 0 C after 3 months storage at these temperatures.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
There is provided according to the invention a non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and 5 (ii) a solvent comprising ethanol which composition is substantially free of chloride.
Description
BUPRENORPHINE-CONTAINING NON-PRESSURISED SPRAY COMPOSITION FOR TRANSMUCOSAL ADMINISTRATION
This invention relates to compositions of buprenorphine especially pump spray compositions suitable for transmucosal, particularly sublingual, delivery.
Buprenorphine, with structure shown below, is a partial agonist of opiate receptors which is widely used for the treatment of moderate to severe pain or in the treatment of opiate dependence.
Buprenorphine is often described as a partial agonist (receptor stimulator)/antagonist (prevents receptor stimulation). It has important actions on two types of opiate receptors in the brain. Many of the most common opioid effects, such as euphoria, respiratory effects and reduced pain sensation, are caused by stimulation of the mu receptor. Buprenorphine stimulates this receptor, albeit at lower intensity than other opiates such as heroin or methadone. This lower level of stimulation is of benefit clinically in people with respiratory compromise but require opioid medication, such as the elderly.
Buprenorphine is also an antagonist of the kappa opioid receptor, which is associated with some of the negative effects experienced in withdrawal, particularly depression. As buprenorphine inhibits stimulation of this receptor it may produce feelings of well-being. Finally, its disassociation from these receptors is slow, leading to a long duration of action, allowing once daily dosing and sometimes dosing every two days, making buprenorphine a versatile treatment option in treatment of drug addiction.
A number of presentations of buprenorphine are currently available. Low-dose sub-lingual tablets, containing 0.2-0.4 mg of the drug as hydrochloride, are sold under the brand name Temgesic and are normally used for analgesic purposes. Temgesic brand of buprenorphine hydrochloride is also available as ampoules for intramuscular or slow intravenous injection. The
most common formulation of buprenorphine used for the treatment of opiate dependence is sublingual tablets containing 0.4, 2 and 8 mg buprenorphine hydrochloride and available under the brand name Subutex. Using a combination of tablets, doses of up to 32 mg may be administered. These tablets are specifically intended for the treatment of problem drug use in patients who are being maintained in medically assisted treatment; in the case of patients undergoing withdrawal treatment, they are administered in a gradually reducing dose. Low-dose sublingual tablets are sometimes used for the treatment of opiate dependence, in which case multiple tablets are prescribed in order to achieve the desired dose.
A liquid formulation for sub-lingual administration is described in GB2100985 (Todd). Specifically, this document describes formulations containing buprenorphine or a non-toxic salt thereof, but especially buprenorphine hydrochloride, dissolved in 20-30% v/v ethanol in water buffered to a pH of between 4.5-5.5 with 0.05-0.2 molar concentration of a buffering agent selected from citric acid/disodium hydrogen phosphate, sodium citrate/hydrochloric acid, lactic acid/disodium hydrogen phosphate, lactic acid/sodium lactate, sodium citrate/citric acid and sodium acetate/acetic acid, the concentration of buprenorphine being between 0.8 and 10 mg/ml (i.e. around 0.08-1.0% w/v) of the composition. The Examples relate to buprenorphine hydrochloride solutions containing various different concentrations of ethanol and a variety of buffers. The compositions do not appear to be sprays as the document refers to the volume of liquid that a patient can hold sublingually for a reasonable amount of time.
It is well known that the application of carefully chosen medicaments to mucosa, for example the sublingual mucosa, offers a route of administration which is capable of resulting in very rapid transmission of medicament to the bloodstream with consequent fast onset of effect. Other mucosa to which medicaments may be administered include the nasal mucosa and buccal mucosa. A number of ways of administering compositions sublingually are known. For example, tablets or liquids may be held under the tongue prior to swallowing. Another method is spray delivery. Of these various types of sublingual administration, spray delivery is preferred as it does not involve holding the composition under the tongue for an extended period of time as, for example, with a lozenge and it reduces the amount of material which is swallowed (and may enter the blood stream in a delayed manner via the gastrointestinal tract). However it is not considered desirable to spray large volumes of liquid (eg greater than around 500 uL) to the sublingual cavity.
WO01/97780 (Ross) describes a pharmaceutical composition comprising a solution of an opioid analgesic (especially fentanyl, although buprenorphine is referred to) and a propellant, for sublingual aerosol administration. The example formulations are pressurized and therefore
require complex packaging and actuation technology. Also they employ halogenated propellants which may not be environmentally friendly.
Weinberg et al (1988) Clin Pharmacol Ther 44, 335-342 discusses the adsorption of various opioids including buprenorphine (presented in an aqueous phosphate buffer at pH 6.5) when administered by pipette in liquid form to the sublingual cavity.
WO01/89476 (Pinney et al) discloses buffered compositons for transmucosal delivery. Buprenorphine is mentioned in a very long list of possible active agents and is not exemplified.
Presently there are no spray compositions containing buprenorphine which have been made available commercially.
Thus an object of the present invention is to provide a spray composition containing buprenorphine for transmucosal, particularly sublingual, administration. Further objects of the invention are to provide a spray composition containing buprenorphine for transmucosal (eg sublingual) administration with good physical properties, especially good stability and low environmental impact, and good biological properties, especially rapid onset of activity and efficacy at relatively low doses. Such a composition would mitigate many of the disadvantages of prior art compositions containing buprenorphine.
Thus according to a first aspect of the invention there is provided a non-pressurised pharmaceutical liquid solution spray composition comprising:
(i) buprenorphine; and
(ii) a solvent comprising ethanol; characterised in that the composition is substantially free of chloride.
The composition is non-pressurised i.e. is substantially free of any propellant. Exemplary propellants to be substantially avoided include volatile substances which develop significant vapour pressure at ambient temperature and pressure such as lower alkanes (eg propane, butane and the like) and halogenated hydrocarbons such as CFCs (P12 etc) and hydrofluorocarbons (P134a, P227 etc) as well as other propellants commonly used in aerosol presentations. Use of P1 1 is also preferably substantially avoided. By "substantially free" or "substantially avoided" is meant that an amount of less than 5% w/w based on weight of composition is employed, suitably less than 2% eg less than 0.1 % w/w. Preferably propellants are avoided altogether.
The concentration of the buprenorphine in the composition may typically vary between 0.05 and 12% w/v, more suitably 0.1-10% w/v, eg 0.1-4% w/v or especially 2-8% w/v, for example 4-8% w/v eg 4% or 8% w/v (all figures being based on weight of buprenorphine base relative to total weight of composition).
By "substantially free of chloride" is meant that the formulation has a substantial absence of chloride in ionised (i.e. such that Cl" is formed in solution) or unionised form. The reason for the substantial absence of chloride is to avoid the precipitation of buprenorphine hydrochloride which is not highly soluble in aqueous or ethanolic solvents. Thus the amount of chloride in the composition is suitably less than 3% w/w based on weight of buprenorphine eg less than 1 % w/w, eg less than 0.5% w/w for example less than 0.1 % w/w, especially when the pH of the composition is less than 7.
Preferably the buprenorphine is employed as base or as citrate, particularly as base.
An advantage of the invention, and in particular of use of buprenorphine in a formulation which is substantially free of chloride, is that relatively concentrated compositions can be prepared which allows for administration of high doses of buprenorphine without using excessively large metering volumes. For example, as will be explained below, we have successfully prepared solutions of concentration 4 and 8% w/v, whereas buprenorphine hydrochloride has not proved soluble in water or ethanol at these concentrations. These higher concentrations of buprenorphine are achieved by using a solvent containing a significant amount of ethanol and the highest concentrations are achieved by lowering the pH with citric acid.
Some sprayable non-pressurised analgesic compositions are taught in the art, for example in WO02/094234 (Rabinowitz), WO 03/080022 (Birch) and WO 2004/071491 (Blondino). WO02/094234 relates to an opioid-containing aerosol formulation for administration by inhalation. The formulations are all aqueous solutions with no other solvent being suggested. WO 03/080022 relates to aqueous solutions comprising an analgesic for intranasal administration. The analgesic may be buprenorphine or a salt thereof but there is no teaching that the composition should not contain chloride and indeed the examples all relate to compositions comprising buprenorphine hydrochloride. There is no suggestion that ethanol could be included in the solvent. WO 2004/071491 relates to liquid aerosol formulations in which the solvent may contain ethanol. There is no suggestion that it would be advantageous to provide a chloride-free composition and all of the examples relate to formulations containing buprenorphine hydrochloride.
Generally speaking it will be desired to employ the least amount of solvent necessary (or a modest excess over that necessary) to adequately solubilise the buprenorphine such that the buprenorphine remains in solution under the conditions of likely usage or exposure.
Typically the solvent is selected from ethanol and ethanol/water mixtures. In a first embodiment of the invention ethanol is substantially the only solvent. For example the concentration of ethanol in the solvent is greater than 90% w/w eg greater than 95% w/w particularly greater than 98% w/w, for example around 100% w/w (i.e. the solvent is ethanol, the presence of any water as contaminant from the atmosphere being ignored). In this first embodiment of the invention use of water as solvent is substantially avoided, for example the water concentration is less than 10% w/w eg less than 5% w/w particularly less than 98% w/w, for example around 0% w/w (i.e. the composition is substantially free of water). As noted below, avoidance of water can be advantageous especially in formulations of buprenorphine containing citrate since we have observed that such formulations have a tendency to turn pink on storage.
In a second embodiment of the invention the solvent comprises water as well as ethanol. For example the solvent consists of a water/ethanol mixture in which the concentration of ethanol is approximately 30-90% w/w (the balance being water) for example approximately 40-70% w/w eg around 50% w/w.
Preferably water when employed as solvent meets the USP (US Pharmacopoeia), EP (European Pharmacopoeia) "Purified Water" standards.
The pH of the solution may typically be between around 4 and 9.5 however will preferably be between around 4.5 and 9. In a first embodiment of the invention the pH is between 4 and 6 eg between around 4.5 and 6 eg around 5 or between around 4 and 5 eg around 4.5. In a second embodiment of the invention, the pH is greater than 7 for instance between around 8 and 9.5 eg between around 8 and 9 eg around 8.5. It is envisaged that compositions at this higher pH will be more efficacious and/or have more rapid activity. Without being limited by theory it is envisaged by the inventors that buprenorphine will be more rapidly or efficiently adsorbed through the mucosa, especially the sublingual mucosa, at a pH close to the pKa of buprenorphine, which is 8.5 (Pharmaceutical Codex). Compositions of pH above 7 have not thus far been described in concrete terms, presumably due to the predominant use of buprenorphine hydrochloride and the problems of solubility of the active at higher pH. Such problems are substantially overcome by use of compositions of the invention.
By "pH" is meant the pH reading that would be obtained using a conventional pH meter eg model pH 21 1 manufactured by Hanna Instruments Ltd and Orion 420A manufactured by
Thermo Electron Corporation (i.e. in water free systems the word "pH" would be construed to mean "apparent pH").
In order to adjust the pH buffer salts can be employed, however we have found that careful attention must be paid to the concentration of these due to the insolubility of many organic and inorganic salts in substantially ethanolic solvents. When buffers are employed, the preferred buffer system for lower pH ranges is citrate (eg sodium citrate)/citric acid which does have adequate solubility in ethanolic solvents. However citrate/citric acid is itself problematic since we have found that compositions of the invention containing citrate/citric acid and water have a tendency to turn pink on storage especially at elevated temperature. Accordingly use of buffer salts and even citrate/citric acid is preferably avoided.
Suitably the use of phosphate containing buffers (eg phosphate and protonated derivatives such as hydrogen and dihydrogen phosphate) is also avoided. Thus the amount of phosphate in the composition (eg as phosphate per se or as a protonated derivative such as hydrogen or dihydrogen phosphate) is suitably less than 3% w/w based on weight of buprenorphine eg less than 1 % w/w, eg less than 0.5% w/w for example less than 0.1 % w/w especially when the pH of the composition is less than 7.
We have found nevertheless that citric acid is useful to enhance the solubility of buprenorphine base in ethanolic solvents (eg to concentrations of 4% w/v or higher eg 4-8% w/w (based on total weight of composition) particularly 5-8% w/w). In such compositions the solvent may (most suitably) be essentially ethanol (eg 100% ethanol) or may (alternatively) contain water (eg ethanol/water 1 :1 ). In order to achieve these higher concentrations typically citric acid may be employed at a concentration of around 0.1-10% w/w eg 0.2-5% w/v eg 0.2-2% w/w.
In order to address the issue of pH adjustment of buprenorphine solutions and in particular without use of conventional buffer salts or use of chloride (eg as HCI) the inventors have appreciated that it may be possible to achieve this by the use of other organic formulation components. Accordingly we undertook a careful assessment of the impact on pH on buprenorphine solutions by addition of saccharin or sodium saccharin optionally together with certain other formulation components such as menthol (eg L-menthol) or peppermint oil.
As a result of our investigations we discovered that the pH of buprenorphine base in ethanol is not significantly affected by buprenorphine concentration. However we surprisingly discovered that saccharin may be effectively employed to lower the pH of buprenorphine base compositions, and is particularly useful in achieving a pH in the range 4-6, particularly 4.5-6 eg around 5. The pH lowering effect of saccharin lessens with increased buprenorphine
concentration. Addition of menthol (eg L-menthol) or peppermint oil has relatively little impact on pH when in conjunction with saccharin.
We also discovered that saccharin sodium as well as menthol (eg L-menthol) and peppermint oil all have a modest but potentially useful effect on raising the pH of buprenorphine base compositions in ethanol, and is particularly useful in achieving a pH in the range between about 8 and 9.5 eg between around 8 and 9 eg around 8.5.
The above mentioned results are illustrated in Figures 1 and 2.
As well as their above mentioned useful properties in modifying the pH of the compositions, saccharin and saccharin sodium are useful as sweeteners which improve patient acceptability.
As well as their above mentioned useful properties in modifying the pH of the compositions, menthol (eg L-menthol) and/or peppermint oil are useful as flavourings and moisturing agents which may have penetration enhancing activity.
The properties of the claimed compositions may be further improved by including therein a number of additional formulation components.
It may be desirable to include one or more of the following components in the composition
- sweeteners such as saccharin, saccharin sodium, sucrose, flavouring or taste-masking agents
(to improve patient acceptability),
-moisturising agents (to improve patient comfort and overcome the drying tendency of ethanol and other polar organic solvents) for example peppermint oil, menthol (eg L-menthol) pineapple extract, lanolin, polypropylene glycol, polyethylene glycol.
-mucoadherents (in order to increase residency time on the mucosa) for example carboxyvinyl polymers, chitosans, polyacrylic acid, gelatin, polyvinyl pyrrolidone.
-preservatives (to improve long term resistance to microbial contamination) for example sodium metabisulphite, benzalkonium, Nipas.
-antioxidants for example alkyl gallates, butylated hydroxyanisole butylated hydroxytoluene, nordihydroguaiaretic acid, tocopherols, Ascorbic acid, sodium metabisulphite
-anionic surfactants for example magnesium stearate, sodium cetostearyl sulphate, sodium lauryl sulphate, sodium oleate, sodium stearyl fumarate, sodium tetradecyl sulphate
-nonionic surfactants for example glyceryl monostearate, Macrogol cetostearyl ethers,
Poloxamers, polyoxyl stearates, Polysorbates, sorbitan esters, sucrose esters, Tyloxapol, propylene glycol monostearate, Quillaia, polyoxyl, caster oils, nonoxinols, lecithins and derivatives, oleic acid and derivatives, oleyl alcohol and derivatives
-foaming agents for example alginic acid and salts, propylene glycol alginate, sodium lauryl sulphate, sodium cetostearyl sulphate, carbomers, hydroxyethylcellulose
Amongst the above mentioned possible additional components, it may be remarked that a preservative should not normally be necessary in view of the ethanol content of the compositions.
In accordance with best pharmaceutical principles, additional components will be avoided if not necessary.
We have observed that compositions according to the invention which are of higher strength (eg 4 % w/v or above), especially those containing saccharin, have a tendency to yellow on storage, especially at higher temperatures. Accordingly a stabiliser selected from anti-oxidants (eg ascorbic acid/ascorbate) and/or a chelating agent (eg EDTA/sodium edetate) may suitably be employed.
Some of the components proposed above may already be included in the composition of the present invention for other purposes. Suitable moisturising agents include, for example, the polar organic solvents such as glycols, especially propylene glycol, and the liquid polyethylene glycols, glycerol, methylcellulose, hypromellose, hydroxypropylcellulose, and many other substituted celluloses.
As mentioned above, a versatile component, which improves the acceptability and other properties of the composition, is menthol especially L-menthol. Menthol (eg L-menthol), as well as flavouring the composition, has moisturising effect. It may also have effect as a penetration enhancer. Preferably menthol (eg L-menthol) is employed in a concentration range of 0.1 % to 0.75% w/w eg around 0.2% w/w.
Peppermint oil is an alternative component which may be used in place of menthol. Peppermint is known to have incompatibilities with certain actives (eg fentanyl) however it appears to be compatible with buprenorphine. Suitably peppermint oil is employed in a concentration range of 0.1 % to 0.75% w/w eg around 0.5% w/w.
In preferred embodiments of the invention, the composition contains a sweetener. In one embodiment of the invention, the sweetener is saccharin sodium. Suitably the concentration of saccharin sodium is around 0.1-0.9% w/w eg around 0.45% w/w.
In another embodiment of the invention, the composition contains saccharin. Suitably the concentration of saccharin is around 0.025-0.75% w/w, for example around 0.05-0.4% w/w eg around 0.05-0.1 % w/w. As pointed out above the concentration of saccharin may be varied depending on the eventual pH desired (see Figure 2).
A number of compositions of the invention are considered to be especially suitable.
A suitable example composition comprises (or consists essentially of (eg consists of)):
-buprenorphine as base;
-a solvent selected from ethanol and ethanol/water mixtures; wherein the composition is substantially free of chloride; and wherein the pH of the composition is greater than 7.
The pH of the composition may, for instance, be between around 8 and 9.5 eg between around
8 and 9 eg around 8.5.
The solvent may suitably be ethanol.
Optionally (and advantageously) such compositions comprise saccharin sodium.
Optionally (and advantageously) such compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
Optionally such compositions comprise a chelating agent (eg EDTA or sodium edetate).
Optionally such compositions comprise an anti-oxidant.
Optionally hydroxide (eg NaOH, KOH) may be used to raise the pH if needed.
Suitably the concentration of buprenorphine base is 0.1-4% w/v.
Another suitable example composition comprises (or consist essentially of (eg consist of)):
-buprenorphine as base;
-a solvent selected from ethanol and ethanol/water mixtures;
-saccharin; wherein the composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6 eg between around 4.5 and 6 eg around 5.
The solvent may suitably be ethanol.
Optionally (and advantageously) such compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
Optionally such compositions comprise a chelating agent (eg EDTA or sodium edetate).
Optionally such compositions comprise an anti-oxidant.
Suitably the concentration of buprenorphine base is 0.1-4% w/v.
Another suitable example composition comprises (or consist essentially of (eg consist of)): -buprenorphine as base at a concentration of 4% w/v or more;
-a solvent selected from ethanol and ethanol/water mixtures;
-citric acid; wherein the composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6 eg between around 4 and 5 eg around 4.5.
The solvent may suitably be ethanol.
Optionally (and advantageously) such compositions comprise a flavouring agent selected from menthol (eg L-menthol), peppermint oil and mixtures thereof.
Optionally (and advantageously) such compositions comprise saccharin.
Optionally such compositions comprise a chelating agent (eg EDTA or sodium edetate).
Optionally such compositions comprise an anti-oxidant.
Suitably the concentration of buprenorphine base is 4-8% w/v.
A process for preparation of compositions of the invention comprises:
(a) taking buprenorphine as base and a solvent comprising ethanol optionally containing the other formulation ingredients (eg saccharin, saccharin sodium, menthol, peppermint oil etc) and dissolving the buprenorphine in the solvent; or
(b) taking buprenorphine as base and a solvent comprising ethanol and dissolving the buprenorphine in the solvent, then adding the other formulation ingredients (eg saccharin, saccharin sodium, menthol, peppermint oil etc); or
(c) the process of (a) or (b) in which the pH of the solvent is adjusted (eg with citric acid) once all the other formulation ingredients are mixed together.
Amongst the advantages of the claimed compositions is the fact that by being non-pressurised they avoid the issues associated with using propellant, such as their manufacturing disadvantages and their potential environmental impact (many propellants are "greenhouse gasses"). The solution compositions of the invention are homogenous and have limited or no susceptibility to dose-to-dose variation. Furthermore compositions of the present invention are characterised by good long-term physical and chemical stability.
The compositions of the invention are preferably administered transmucosally (particularly sublingually) as a spray. The compositions are expected to be well tolerated when administered to the sensitive sublingual mucosa and the sublingual spray administration will result in rapid onset of the therapeutic effect of the buprenorphine.
Thus according to a second aspect of the invention there is provided a metered dose dispensing system comprising a sealed container containing a composition of the invention fitted with a metering pump, an actuator and a channelling device. The metered dose dispensing system is preferably adapted for transmucosal (particularly sublingual) administration.
Although in principle the container for the pharmaceutical liquid composition may contain a single dose of buprenorphine (which may, nevertheless be a divided dose), preferably the container will contain a plurality of doses (eg 20 to 200 doses) of buprenorphine.
Although the composition could be packaged in a suitable pharmaceutical grade, plastics container, such a container would be relatively easy to open for abuse of the product. Therefore a glass container would be more suitable. Glass would shatter if attempts were made to open the pack, rendering the contents either lost or unusable due to glass fragments. Preferably the glass container will be coated on the exterior with a suitable moulded film of plastic to protect against shattering. For example the film may be of polypropylene. The material may be coloured and contain a UV absorber. The container glass may be colourless or more suitably may be provided with a UV protective colouring, for example amber colouring. Optionally, the interior of the container can be coated to enhance stability of the product. Coatings include polymers and lacquers but also silicone dioxide as an unreactive coating can be used to line the inside of the container.
Since the composition is non-pressurised, it is suitably administered to the patient by pump action. Thus the metering dose dispensing system suitably contains a metering pump permitting a metered dose of the composition to be administered as a spray.
Suitable metering pumps include those adapted for dispensation with the container in the upright or inverted orientation. Preferably the metering chamber is adapted for dispensation with the container in the upright orientation since this facilitates administration under the tongue. Accordingly the metering chamber will be in communication with the composition by means of a dip-tube.
The metering pump is suitably a non-venting type. Suitable materials of construction include polypropylene and polyethylene. Example metering pumps are those manufactured by Valois (eg VP3, VP6, VP7 and VP7D) and for example those illustrated in International Patent Application No. WO01 /66089. Other conventional pumps include those from Rexam (eg SP270) and Calmar (eg Accupump or Mistette Mk II).
Preferably the actuator will be designed to deliver a transmucosally (particularly a sublingually) effective dose. The pump may suitably be manually actuated, although assisted actuation using stored energy (eg spring or gas) may be contemplated.
For a secure seal, the pump is suitably crimped onto the container neck. Suitable sealing materials eg thermo plastic crimp gaskets suitable for the purpose will be employed. In addition, a suitable aluminium ferrule purposely designed for crimping on to glass containers may suitably be employed. Suitable grade stainless steel springs will preferably be adopted.
The metering pump will administer a metered volume of composition. Suitable metering volumes are 10-1000 uL, more suitably 50-250 uL, eg 10OuL or 200 uL, particularly 200 uL.
A channelling device is provided to direct the liquid sprayed from the metered dose dispensing area to the appropriate part of the mouth e.g. to the sublingual cavity or if desired to the nose. Channelling devices are suitably fabricated from moulded plastics. A number of channelling devices adapted to administer sprays to the mouth or nose are known to persons skilled in the art eg
Compositions of the invention are useful in treatment or prevention of opiate dependency and abuse, particularly in the treatment or prevention of dependency on opiates such as heroin and for analgesic purposes eg for the treatment of moderate to severe pain. Thus in a further aspect of the invention there is provided a method of treatment or prevention of opiate dependency and abuse or pain which comprises administering to a subject in need thereof an effective amount of a composition of the invention. In a further aspect of the invention, there is provided the use of a composition according to the invention in the manufacture of a medicament for the treatment or prevention of opiate dependency and abuse or pain. In a further aspect, there is provided a composition of the invention for use in the treatment or prevention of opiate dependency and abuse or pain.
In order to lessen the risk of abuse with the product, suitably the container or the dispensing system may be provided with features to prevent tampering. In particular, the container or the dispensing system may suitably be provided with features to prevent or discourage access to the reservoir and/or to prevent administration of more than one dose of buprenorphine at one time.
The dispensing system, in particular the actuator, may, for example, be provided with a lock-out feature to prevent administration of a second dose within a specified time interval of the first. Lock-out features are, for example, described in US2006191532, WO03097141 and WO0232487.
Typically a patient is treated by administration transmucosally (eg sublingually) of 1 to 4 actuations eg 1 or 2 actuations from the spray pump. Another advantage of mucosal spray delivery is the ability to easily titrate patients by 1 or 2 doses as required by a single actuation. This is not the case with other forms of drug delivery (patches, lozenges, tablets, suppositories).
Pharmaceutical compositions of the invention are useful in the treatment of animals, particularly non-human mammals (for example domestic or livestock animals) as well as humans. Accordingly pharmaceutical uses, for example uses in the treatment of pain, may be extended to veterinary uses. Dosages and methods of administration (eg the spray actuator design) will be adapted for the intended recipient as would be known to a skilled person.
Examples
Examples 1-4
Com ositions were re ared as follows:
The compositions formed a clear colourless solution at 4, 25 and 40 0C and remained so after 1 month storage at these temperatures.
Examples 5-8
Compositions were prepared as follows:
The compositions formed a clear colourless solution at 4, 25 and 40 0C and remained so after 2 weeks storage (Example 8) or 1 month storage (Examples 5-7) at these temperatures.
Examples 9-12
Compositions were prepared as follows:
The compositions formed a clear colourless solution at 4, 25 and 40 0C and remained so after 1 month storage at these temperatures.
Examples 13-16
Compositions were prepared as follows:
NM not measured
Example 13: the composition formed a clear colourless solution at 4, 25 and 40 0C. and remained so after 2 months storage at these temperatures.
Example 14: the composition formed a clear colourless solution at 4 and 25 0C and a clear very light yellow solution at 4O0C after 2 months storage at these temperatures.
Examples 15, 16: the compositions formed a clear colourless solution at 4 and 25 0C and a clear light yellow solution at 4O0C after 3.5 months storage at these temperatures.
Examples 17-20
Compositions were prepared as follows:
NM not measured
Examples 17 and 18: the compositions formed a clear colourless solution at 4 and 25 0C and a dark yellow solution at 4O0C after 3.5 months storage at these temperatures.
Example 19: the composition formed a clear light yellow solution at 4 0C, a clear yellow solution at 25 0C and a clear dark yellow solution at 4O0C after 3.5 months storage at these temperatures.
Example 20: the composition formed a clear colourless solution at 4 0C, a clear light yellow solution at 25 0C and a clear yellow solution at 4O0C after 2 months storage at these temperatures.
Examples 21-24
Compositions were prepared as follows:
Examples 21 and 22: the compositions formed a clear colourless solution at 4, a light yellow solution at 25 0C and a yellow solution at 4O0C after 3 months storage at these temperatures. Example 23: the composition formed a clear colourless solution at 4 0C and 25 0C and a clear pink solution at 4O0C after 3 months storage at these temperatures.
Example 24: the composition formed a clear colourless solution at 4 0C and 25 0C and a clear light pink solution at 4O0C after 3 months storage at these temperatures.
Example 25
The dependence of apparent pH on buprenorphine base concentration in ethanol solution was investigated for various compositions. The results are shown in Figure 1.
The most striking observation is that saccharin has a significant effect on the composition apparent pH, which decreases with buprenorphine base concentration. The overlapping profiles at markedly lower pH was obtained from the 3 compositions containing (i) saccharin; (ii) saccharin with peppermint oil; and (iii) saccharin with L-menthol.
Example 26
The dependence of apparent pH on saccharin concentration in buprenorphine base (0.2% w/v) / ethanol solution was investigated for various compositions. The results are shown in Figure 2.
Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.
The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:
Claims
1. A non-pressurised pharmaceutical liquid solution spray composition comprising: (i) buprenorphine; and
(ii) a solvent comprising ethanol characterised in that the composition is substantially free of chloride.
2. A composition according to claim 1 wherein the concentration of ethanol in the solvent is greater than 90% w/w.
3. A composition according to claim 1 or claim 2 which is substantially free of water.
4. A composition according to claim 2 or claim 3 wherein the concentration of ethanol in the solvent is around 100% w/w.
5. A composition according to claim 1 wherein the concentration of ethanol in the solvent is approximately 30- 90% w/w, the balance being water.
6. A composition according to any one of claims 1-5 wherein the concentration of buprenorphine in the composition is around 0.05-12% w/v.
7. A composition according to claim 6 wherein the concentration of buprenorphine in the composition is around 2-8% w/v.
8. A composition according to any one of claims 1 -7 wherein the pH of the composition is between around 4 and 6.
9. A composition according to any one of claims 1 -7 wherein the pH of the composition is between around 8 and 9.5.
10. A composition according to claim 8 which contains saccharin.
1 1. A composition according to claim 9 which contains saccharin sodium.
12. A composition according to any one of claims 1 to 11 which contains menthol.
13. A composition according to any one of claims 1 to 12 which contains peppermint oil.
14. A composition according to claim 1 comprising: -buprenorphine as base;
-a solvent selected from ethanol and ethanol/water mixtures; wherein the composition is substantially free of chloride; and wherein the pH of the composition is greater than 7.
15. A composition according to claim 14 wherein the pH of the composition is between around 8 and 9.
16. A composition according to claim 14 or claim 15 which comprises saccharin sodium.
17. A composition according to claim 1 which comprises -buprenorphine as base;
-a solvent selected from ethanol and ethanol/water mixtures;
-saccharin; wherein the composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6.
18. A composition according to any one of claims 14 to 17 wherein the concentration of buprenorphine base is 0.1-4% w/v.
19. A composition according to claim 1 which comprises: -buprenorphine as base at a concentration of 4% w/v or more; -a solvent selected from ethanol and ethanol/water mixtures; -citric acid; wherein the composition is substantially free of chloride; and wherein the pH of the composition is between around 4 and 6.
20. A composition according to claim 19 which comprises saccharin.
21. A composition according to any one of claims 14 to 20 wherein the solvent is ethanol.
22. A composition according to claim 19 or claim 20 wherein the solvent is an ethanol/water mixture.
23. A composition according to any one of claims 14 to 22 which comprises a flavouring agent selected from menthol, peppermint oil and mixtures thereof.
24. A composition according to any one of claims 14 to 23 which comprises a chelating agent.
25. A composition according to any one of claims 14 to 24 which comprises an anti-oxidant.
26. A composition according to any one of the preceding claims for transmucosal administration as a spray.
27. A composition according to claim 26 wherein the transmucosal administration is sublingual administration.
28. A composition according to any one of the preceding claims, for use in the treatment or prevention of opiate dependency or abuse or pain.
29. Use of a composition according to any one of claims 1 to 28 in the manufacture of a medicament for the treatment or prevention of opiate dependency or abuse or pain.
30. A sealed container containing a plurality of doses of a composition according to any one of claims 1 to 28.
31. A container according to claim 30 which is made out of glass.
32. A metered dose dispensing system comprising a sealed container according to claim 30 or claim 31 fitted with a metering pump, an actuator and a channelling device.
33. A metered dose dispensing system according to claim 32 containing a metering chamber which is adapted for dispensation with the container in the upright orientation and wherein the metering chamber is in communication with the composition by means of a dip- tube.
34. A metered dose dispensing system according to claim 32 or claim 33 adapted for transmucosal administration of the composition as a spray.
35. A metered dose dispensing system according to claim 34 wherein the transmucosal administration is sublingual administration.
36. A process for preparation a composition according to any one of claims 1 to 28 which comprises:
(a) taking buprenorphine as base and a solvent comprising ethanol optionally containing the other formulation ingredients and dissolving the buprenorphine in the solvent; or
(b) taking buprenorphine as base and a solvent comprising ethanol and dissolving the buprenorphine in the solvent, then adding the other formulation ingredients; or
(c) the process of (a) or (b) in which the pH of the solvent is adjusted once all the other formulation ingredients are mixed together.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0620661.9A GB0620661D0 (en) | 2006-10-18 | 2006-10-18 | Novel compounds |
PCT/GB2007/050639 WO2008047163A1 (en) | 2006-10-18 | 2007-10-17 | Buprenorphine-containing non-pressurised spray composition for transmucosal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2081574A1 true EP2081574A1 (en) | 2009-07-29 |
Family
ID=37507923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07824851A Withdrawn EP2081574A1 (en) | 2006-10-18 | 2007-10-17 | Buprenorphine-containing non-pressurised spray composition for transmucosal administration |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2081574A1 (en) |
CN (1) | CN101573116A (en) |
AU (1) | AU2007311621A1 (en) |
CA (1) | CA2666581A1 (en) |
GB (2) | GB0620661D0 (en) |
IL (1) | IL197908A0 (en) |
WO (1) | WO2008047163A1 (en) |
ZA (1) | ZA200902123B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10010612B2 (en) | 2007-05-25 | 2018-07-03 | Indivior Uk Limited | Sustained delivery formulations of risperidone compounds |
US10022367B2 (en) | 2014-03-10 | 2018-07-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
US10058554B2 (en) | 2005-09-30 | 2018-08-28 | Indivior Uk Limited | Sustained release small molecule drug formulation |
US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
US10198218B2 (en) | 2010-06-08 | 2019-02-05 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2577390T3 (en) | 2006-07-21 | 2016-07-14 | Biodelivery Sciences International, Inc. | Transmucosal administration devices with greater uptake |
GB2461681A (en) * | 2008-04-17 | 2010-01-13 | Pharmasol Ltd | Buprenorphine liquid spray formulation with solvent and antioxidant |
WO2010072398A2 (en) * | 2008-12-22 | 2010-07-01 | Boehringer Ingelheim Limited | Veterinary formulations |
GB2483579A (en) * | 2010-06-30 | 2012-03-14 | Londonpharma Ltd | Sublingual formulations comprising methadone and ethanol for use in reducing pain |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
EP2793870A4 (en) * | 2011-12-21 | 2016-02-17 | Biodelivery Sciences Int Inc | Transmucosal drug delivery devices for use in chronic pain relief |
CA3003293A1 (en) | 2015-10-27 | 2017-05-04 | Insys Development Company, Inc. | Liquid buprenorphine formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001097780A2 (en) * | 2000-06-22 | 2001-12-27 | Pharmasol Ltd | Pharmaceutical compositions comprising an opioid analgesic |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2004071491A1 (en) * | 2003-02-04 | 2004-08-26 | Chrysalis Technologies Incorporated | Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem |
ES2559410T3 (en) * | 2004-04-23 | 2016-02-12 | Philip Morris Products S.A. | Aerosol generators and methods for producing aerosols |
-
2006
- 2006-10-18 GB GBGB0620661.9A patent/GB0620661D0/en not_active Ceased
-
2007
- 2007-10-17 AU AU2007311621A patent/AU2007311621A1/en not_active Abandoned
- 2007-10-17 EP EP07824851A patent/EP2081574A1/en not_active Withdrawn
- 2007-10-17 CN CNA2007800387417A patent/CN101573116A/en active Pending
- 2007-10-17 CA CA002666581A patent/CA2666581A1/en not_active Abandoned
- 2007-10-17 WO PCT/GB2007/050639 patent/WO2008047163A1/en active Application Filing
-
2009
- 2009-03-25 GB GB0905120A patent/GB2456434A/en not_active Withdrawn
- 2009-03-26 ZA ZA200902123A patent/ZA200902123B/en unknown
- 2009-04-05 IL IL197908A patent/IL197908A0/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2008047163A1 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10058554B2 (en) | 2005-09-30 | 2018-08-28 | Indivior Uk Limited | Sustained release small molecule drug formulation |
US11110093B2 (en) | 2005-09-30 | 2021-09-07 | Indivior Uk Limited | Sustained release small molecule drug formulation |
US10010612B2 (en) | 2007-05-25 | 2018-07-03 | Indivior Uk Limited | Sustained delivery formulations of risperidone compounds |
US10376590B2 (en) | 2007-05-25 | 2019-08-13 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
US11013809B2 (en) | 2007-05-25 | 2021-05-25 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
US11712475B2 (en) | 2007-05-25 | 2023-08-01 | Indivior Uk Limited | Sustained delivery formulations of risperidone compound |
US10172849B2 (en) | 2010-06-08 | 2019-01-08 | Indivior Uk Limited | Compositions comprising buprenorphine |
US10198218B2 (en) | 2010-06-08 | 2019-02-05 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10558394B2 (en) | 2010-06-08 | 2020-02-11 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10592168B1 (en) | 2010-06-08 | 2020-03-17 | Indivior Uk Limited | Injectable flowable composition comprising buprenorphine |
US10022367B2 (en) | 2014-03-10 | 2018-07-17 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
US10517864B2 (en) | 2014-03-10 | 2019-12-31 | Indivior Uk Limited | Sustained-release buprenorphine solutions |
Also Published As
Publication number | Publication date |
---|---|
GB2456434A (en) | 2009-07-22 |
GB0905120D0 (en) | 2009-05-06 |
GB0620661D0 (en) | 2006-11-29 |
CN101573116A (en) | 2009-11-04 |
WO2008047163A1 (en) | 2008-04-24 |
CA2666581A1 (en) | 2008-04-24 |
IL197908A0 (en) | 2009-12-24 |
AU2007311621A1 (en) | 2008-04-24 |
ZA200902123B (en) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2081574A1 (en) | Buprenorphine-containing non-pressurised spray composition for transmucosal administration | |
US20090270438A1 (en) | Novel compositions and formulations | |
US6632842B2 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
US20060062812A1 (en) | Novel compositions | |
WO2009127878A1 (en) | A liquid spray solution comprising buprenorphine, ethanol and an antioxidant | |
CA2673049C (en) | Stable anti-nausea oral spray formulations and methods | |
US20030191151A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
WO2003037159A2 (en) | An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
IE920484A1 (en) | Pharmaceutical Formulations | |
US20220387421A1 (en) | Drug products for intranasal administration and uses thereof | |
US20030203930A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
AU2004218876B2 (en) | Novel compositions containing fentanyl | |
US20210330903A1 (en) | Multiple Dose Nasal Spray of Naloxone | |
CN1784228B (en) | Novel compositions | |
ES2596359T3 (en) | Pharmaceutical dosage forms of tizanidine and its route of administration | |
US20240226093A1 (en) | Drug products for intranasal administration and uses thereof | |
US20240216360A1 (en) | Drug products for intranasal administration and uses thereof | |
US20110247613A1 (en) | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | |
CA3150070A1 (en) | Pharmaceutical composition | |
KR20130142990A (en) | Pharmaceutical compositions for sublingual delivery of opioids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090415 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110503 |